News for Nuvalent, Inc. (NUVL)

Wall Street seems to be breathing a little easier after the initial panic over President Trump’s tariffs earlier this month, but the rollercoaster is not over just yet.

Nuvalent Inc (NUVL), a clinical-stage biopharmaceutical company specializing in targeted cancer therapies, announced on February 28, 2025, that its CEO, James P

PR NewswireCAMBRIDGE, Mass., Feb. 28, 2025 CAMBRIDGE, Mass., Feb. 28, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutica

Nuvalent Inc (NUVL), a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer, has released a comprehensive update on its

PR NewswireCAMBRIDGE, Mass., Feb. 27, 2025 Topline pivotal data expected in 2025 for both TKI pre-treated ROS1-positive and TKI pre-treated ALK-positive NS

Cash Position: $1.1 billion in cash, cash equivalents, and marketable securities as of December 31, 2024, expected to fund operations into 2028.R&D Expenses: $

On February 18, 2025, COMMODORE CAPITAL LP (Trades, Portfolio) made a significant move by acquiring 5,825,000 shares of Solid Biosciences Inc (NASDAQ: SLDB) at

**media[548311]**

On February 19, 2025, Bain Capital Life Sciences Investors, LLC (Trades, Portfolio) made a significant move by acquiring an additional 1,000,000 shares in Solid

On February 19, 2025, Perceptive Advisors LLC made a significant move by acquiring an additional 5,028,033 shares of Solid Biosciences Inc (SLDB). This transact

Overview of the Recent Transaction On December 31, 2024, PERCEPTIVE ADVISORS LLC (Trades, Portfolio) executed a significant transaction involving Applied Therap

On December 31, 2024, Perceptive Advisors LLC made a significant move by reducing its stake in Amicus Therapeutics Inc (FOLD). The firm decreased its holdings b

Transaction Overview On December 31, 2024, PERCEPTIVE ADVISORS LLC (Trades, Portfolio) executed a notable transaction by acquiring an additional 5,509,236 share

On February 5, 2025, Paradigm Biocapital Advisors LP (Trades, Portfolio) made a significant move by acquiring an additional 950,162 shares of Cogent Biosciences

On December 31, 2024, SILVERARC CAPITAL MANAGEMENT, LLC (Trades, Portfolio) made a significant move by acquiring an additional 136,463 shares of Elutia Inc, a c

On December 31, 2024, Vanguard Group Inc executed a noteworthy transaction by acquiring additional shares in Nuvalent Inc. The firm added 366,239 shares of Nuva

Nuvalent, Inc. shares have fallen approximately 30% after promising updates on its two lead NSCLC candidates rallied the stock to all-time highs. Read the full report on the stock here.

Nuvalent Inc (NUVL), a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, announced its strategic milestones for 2025, aiming for its f

PR NewswireCAMBRIDGE, Mass., Jan. 13, 2025 Strategy prioritizes most accelerated path to first potential approval Initial NDA submission expected by mid-ye